Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.

IF 0.3 4区医学 Q4 Medicine

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-03-18 DOI:10.1159/000349959

Takeshi Yamada, Toshikazu Moriwaki, Kenji Matsuda, Yoshiyuki Yamamoto, Akinori Sugaya, Daisuke Akutsu, Tetsuya Murashita, Shinji Endo, Ichinosuke Hyodo

{"title":"Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.","authors":"Takeshi Yamada, Toshikazu Moriwaki, Kenji Matsuda, Yoshiyuki Yamamoto, Akinori Sugaya, Daisuke Akutsu, Tetsuya Murashita, Shinji Endo, Ichinosuke Hyodo","doi":"10.1159/000349959","DOIUrl":null,"url":null,"abstract":"Background: A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated interstitial lung disease (ILD) occurred in approximately 1% (19/1767) of patients, causing death in 36.8% of these cases.Case report: We report the case of a 60-year-old Japanese man who developed ILD associated with panitumumab therapy (third-line therapy) for metastatic sigmoid colon cancer involving the liver, lymph nodes, and lungs. 2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, dyspnea, and a fever, and was diagnosed with ILD. Intravenous pulse methylprednisolone treatment led to quick recovery. The patient had some risk factors for ILD associated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors.Conclusion: Further studies are required to elucidate the association between anti-EGFR antibodies and ILD.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 4","pages":"209-12"},"PeriodicalIF":0.3000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000349959","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000349959","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/3/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 6

Abstract

Background: A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated interstitial lung disease (ILD) occurred in approximately 1% (19/1767) of patients, causing death in 36.8% of these cases.

Case report: We report the case of a 60-year-old Japanese man who developed ILD associated with panitumumab therapy (third-line therapy) for metastatic sigmoid colon cancer involving the liver, lymph nodes, and lungs. 2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, dyspnea, and a fever, and was diagnosed with ILD. Intravenous pulse methylprednisolone treatment led to quick recovery. The patient had some risk factors for ILD associated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors.

Conclusion: Further studies are required to elucidate the association between anti-EGFR antibodies and ILD.

查看原文本刊更多论文

帕尼单抗诱导的转移性结直肠癌间质性肺疾病1例

背景:日本一项帕尼单抗上市后调查显示，帕尼单抗相关间质性肺疾病(ILD)发生在约1%(19/1767)的患者中，其中36.8%的患者死亡。病例报告:我们报告了一例60岁的日本男性，他因转移性乙状结肠结肠癌累及肝脏、淋巴结和肺部而接受帕尼珠单抗治疗(三线治疗)，并发ILD。开始帕尼单抗治疗2个月后，患者出现进行性非生产性咳嗽、呼吸困难和发烧，并被诊断为ILD。静脉注射甲基强的松龙脉冲治疗恢复迅速。患者有一些与表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂相关的ILD危险因素。结论:抗egfr抗体与ILD之间的关系有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Onkologie 医学-肿瘤学

CiteScore

0.40

自引率

33.30%

发文量

审稿时长

3 months